AI-Assisted ELISA Biomarker Profiling In MASLD: Integrating Early Detection, Risk Stratification, And Treatment Monitoring
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), now has approved drug treatments. Several circulating biomarkers are measured by enzyme-linked immunosorbent assay (ELISA), including the N-terminal pro-peptide of type III collagen (PRO-C3) and cytokeratin-18 (CK-18) fragments. In this narrative review we ask whether artificial intelligence (AI) can help interpret these ELISA-derived profiles well enough to improve detection of MASLD, fibrosis risk stratification and treatment monitoring beyond what is possible today. We keep the established and the speculative apart. On the established side are the fibrosis-4 (FIB-4) index and the ADAPT score, which combines ELISA-measured PRO-C3 with age, diabetes status and platelet count. On the speculative side are machine learning (ML) models for multi-biomarker panels, ML correction of assay artefacts and biomarker-guided choice of drug. CK-18, Fetuin-A and fibroblast growth factor 21 (FGF21) track with disease activity, but none is a validated stand-alone test for MASH. The resmetirom, semaglutide and emricasan trials also remind us that a biomarker moving in the right direction does not prove a patient is better off. We conclude that combining ELISA, AI and precision pharmacotherapy is a reasonable research agenda but not yet a clinical standard, and we set out the validation it still needs.
Authors
- Namita Kamble
- Tushar Ingle
- Hemant Gupta
- Atish Pathak
- Kesar Bankar
- Aastha Patel
- Shubhangi Lal
- Rohan Mane
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24332562
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00